Efficacy and Safety of Aflibercept Therapy for Diabetic Macular Edema: A Systematic Review and Meta-Analysis.

J Curr Ophthalmol · 2022 · PMC9486998 · PMID 36147265

Europe PMC DOI

hedged sentence

0.0560

closest p · 1.1× alpha

0.0560

boldest claim

The sentences

marginally significantP = 0.056so close (0.05 < p ≤ 0.1)

Of four studies that reported complete 24-month mean BCVA outcomes, a marginally significant improvement in BCVA with a pooled mean gain of 6.76 ETDRS letters was noted with aflibercept (WMD = 6.76 ETDRS letters; 95% CI: –0.19–13.70 ETDRS letters; P = 0.056, I 2 = 97.1%) [ Figure 6 ].

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.